Non-Hodgkin Lymphoma

Cell Therapeutics reports complete remission, durable survival data in Pixantrone trial

Published in Healthcare Finance, Tax and Law Weekly, January 10th, 2007

Cell Therapeutics, Inc., (CTI, CTIC, MTAX) announced results from a phase I/II study of patients with relapsed indolent non-Hodgkin lymphoma (NHL) that may identify a potential registration trial for pixantrone.

Among the 27 patients evaluable for response, study results showed the FPD-R regimen with pixantrone produced an 89% overall response rate (ORR), including 63% of patients experiencing a complete disappearance of their disease (complete response, CR). The results were presented at the 48th Annual Meeting of the American Society of Hematology (ASH). The estimated median duration of response was 25 months and the estimated progression-free survival rate at 3 years...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly

Source: Healthcare Finance, Tax and Law Weekly (2007-01-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry